OBSTETRICAL & GYNECOLOGICAL SURVEY妇产科综述
OBSTETRICAL & GYNECOLOGICAL SURVEY(英文缩写 OBSTET GYNECOL SURV),ISSN 0029-7828,eISSN 1533-9866,中文译名:妇产科综述 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 3.015 | Q3 |
| 2022 | 6.200 | Q1 |
| 2023 | 4.300 | Q1 |
| 2024 | 3.600 | Q1 |
| 2025 | 4.700 | Q1 |
OBSTETRICAL & GYNECOLOGICAL SURVEY 最新收录文献
-
1. Preoperative Hyperglycemia in GYN Surgery: Perioperative Considerations.
PMID:日期:2026-08-01There is not clear consensus on perioperative A1C goals in gynecologic (GYN) surgery. To review current literature regarding glycemic control and postoperative outcomes for major GYN surgery for benign, urogynecologic, or oncologic indications. Review conducted using the following databases: MEDLINE via PubMed, Embase via Elsevier, and the Web of Science Core Collection via Clarivate. Included studies were peer-reviewed articles published (1990-current) that examined postoperative complications following major GYN surgery, including hysterectomy, myomectomy, debulking, adnexal mass, vulvectomy, sacrocolpopexy, and percutaneous neurostimulator implants. Data extracted included study design, demographic data, type of surgery, complications, and measure of glycemic control. Of 698 studies, 14 were included: 4 in benign GYN literature, 3 in urogynecology literature, and 7 in GYN oncology literature. In benign GYN literature, hemoglobin A1C values greater than 9% were directly associated with surgical site infection (SSI). In urogynecology, A1C greater than 8% was associated with increased urinary tract infections, wound separation, midurethral sling failure, and composite complications. Finally, in GYN oncology, an A1C greater than or equal to 7% was associated with decreased recurrence-free survival and cancer-specific survival. Preoperative glucose above 110 mg/dL was associated with increased risk of deep vein thrombosis (DVT) in ovarian cancer patients and risk of SSI in endometrial cancer patients. High preoperative A1C is associated with worse postoperative outcomes in the setting of major GYN surgeries. Here we provide guidelines by GYN subspecialty.
-
2. From Survival to Recovery: Long-Term Sequelae of Severe Maternal Morbidity and Obstetric Critical Illness.
2. 从生存到康复：严重孕产妇疾病和产科危重疾病的长期后遗症PMID:日期:2026-08-01[中文摘要] 重度孕产妇疾病（SMM）和产科危重症在美国呈上升趋势，并导致了显著的孕产妇健康差异。尽管重度孕产妇疾病的急性并发症已有充分记录，但其长期躯体和社会心理后果仍研究不足。对重度孕产妇疾病（包括产科危重症）的长期后果及改善健康结局的干预措施进行叙述性综述。采用结构化检索策略在PubMed及相关OpenEvidence检索中筛选原始研究和综述文章；对相关文章进行了审阅。重度孕产妇疾病和产科ICU入住与再入院、慢性心血管和肾脏疾病、精神后遗症（包括创伤后应激障碍）、生活质量下降及不良生殖结局的风险增加相关。特定的孕产妇疾病状况，如妊娠期高血压疾病、围产期心肌病、产后出血和围产期子宫切除术，各自具有不同的长期健康风险。包括多学科专科门诊、向初级保健提供者的结构化照护过渡、社会心理筛查与支持以及扩大产后医疗补助覆盖范围在内的干预措施，在改善孕产妇健康结局和减少差异方面显示出前景。然而，实施仍不一致，且需要纵向数据。重度孕产妇疾病的幸存者承受着超越产后时期的显著长期健康负担。需要整体性、多学科的随访模式和扩展的卫生政策举措，以弥补照护缺口并改善长期孕产妇结局。本综述概述了关于重度孕产妇疾病和产科危重症长期后果的文献。
[英文摘要] Severe maternal morbidity (SMM) and obstetric critical illness are rising in the United States and contribute to striking maternal health disparities. While the acute complications of severe maternal morbidity are well documented, the long-term physical and psychosocial consequences remain understudied. To conduct a narrative review of the long-term consequences of severe maternal morbidity, including obstetric critical illness, and interventions for improving health outcomes. Original and review articles were identified using a structured search strategy in PubMed and relevant OpenEvidence searches; pertinent articles were reviewed. Severe maternal morbidity and obstetric ICU admission are associated with increased risks of hospital readmission, chronic cardiovascular and renal disease, psychiatric sequelae, including posttraumatic stress disorder, reduced quality of life, and adverse reproductive outcomes. Specific maternal morbidity conditions, such as hypertensive disorders of pregnancy, peripartum cardiomyopathy, postpartum hemorrhage, and peripartum hysterectomy, each carry distinct long-term health risks. Interventions including multidisciplinary specialty clinics, structured care transitions to primary care providers, psychosocial screening and support, and expansion of postpartum Medicaid coverage show promise in improving maternal health outcomes and reducing disparities. However, implementation remains inconsistent, and longitudinal data are needed. Survivors of severe maternal morbidity experience significant long-term health burdens that extend beyond the postpartum period. Holistic, multidisciplinary models of follow-up and expanded health policy initiatives are needed to address gaps in care and improve long-term maternal outcomes. This review offers an overview of the literature about the long-term consequences of severe maternal morbidity and obstetric critical illness.
-
3. Clinical Nuances of Preterm Prelabor Rupture of Membranes: A Literature Review.
3. 未足月胎膜早破的临床细微差别：文献综述PMID:日期:2026-07-01Preterm premature rupture of membranes (PPROM) presents significant challenges in obstetric care, particularly due to its association with both maternal and neonatal morbidity. Management becomes even more complex when PPROM occurs in the context of coexisting maternal conditions or atypical clinical scenarios. To review common clinical challenges in the management of PPROM and summarize the available evidence on outcomes and current recommendations. A comprehensive literature search was conducted using PubMed to identify relevant studies, systematic reviews, and practice guidelines. Articles addressing PPROM complicated by concurrent maternal, fetal, or obstetric conditions were reviewed and synthesized. Evidence remains limited in many nuanced clinical scenarios involving PPROM. Studies suggest that outcomes and management may differ in cases of PPROM occurring near the limit of viability, with coexisting infections (eg, HSV or HIV), in the setting of cerclage, or in twin gestations. Although guidelines support expectant management of otherwise uncomplicated cases occurring at <34 0/7 weeks' gestation, individualization of care is often necessary. Factors such as gestational age, presence of infection or labor, cerclage status, and maternal comorbidities influence decision-making. Shared decision-making is critical, and emerging tools, such as amniotic fluid biomarkers, may aid in guiding clinical choices. PPROM management must be tailored to the clinical context. While general recommendations exist, special scenarios require individualized care based on available evidence and patient values. This review provides insight into management strategies and expected outcomes in complex cases of PPROM, supporting clinicians in navigating less straightforward presentations.
-
4. A New Perspective on Endometriosis: How Gut and Reproductive Tract Microbiota Influence Disease Progression?
PMID:日期:2026-07-01Endometriosis, a chronic inflammatory condition affecting 10% of reproductive-aged individuals, remains underdiagnosed and poorly managed due to a limited understanding of its pathogenesis. Emerging evidence highlights the gut and reproductive tract microbiota as key modulators of estrogen metabolism, immune dysregulation, and inflammation, offering novel insights into disease mechanisms and therapeutic opportunities. To synthesize current evidence on the mechanistic roles of microbiota in endometriosis pathogenesis, evaluate the diagnostic and therapeutic potential of microbial biomarkers and microbiota-targeted interventions, and identify priorities for translational research. A systematic review of PubMed, Scopus, and Web of Science databases identified preclinical and clinical studies exploring microbiota-endometriosis interactions. The search strategy incorporated the terms "endometriosis" in combination with "microbiota," "reproductive tract," and "gut" to investigate microbial associations within gastrointestinal and reproductive systems in the context of the disease. Dysbiotic microbial profiles, characterized by reduced Lactobacillus and elevated Fannyhessea species, correlate with altered estrogen metabolism, pro-inflammatory cytokine production (eg, IL-6, TNF-α), and impaired immune surveillance in endometriosis. Preclinical studies demonstrate that probiotics and FMT attenuate lesion growth and inflammation in animal models, though human data remain limited. Noninvasive microbial signatures show promise for diagnostic applications, while causal validation in germ-free models and personalized microbiota-based therapies represent critical research gaps. The microbiota modulates endometriosis progression through hormonal, immune, and inflammatory pathways. Microbial biomarkers and therapies may improve diagnosis and treatment but require rigorous clinical validation. Advancing microbiota research could enable noninvasive diagnostics, precision therapies, and prevention strategies.
-
5. Sentinel Lymph Node Biopsy for Gynecologic Cancers.
5. 妇科癌症的前哨淋巴结活检。PMID:日期:2026-07-01[中文摘要] 淋巴结转移的判定对于妇科肿瘤的预后评估和治疗策略至关重要。采用前哨淋巴结活检（SLNBx）方法评估转移可降低手术并发症并改善生活质量。本综述评估了SLNB在妇科肿瘤中的有效性、安全性和临床实用性，以指导临床实践并指出未来研究方向。通过PubMed、Scopus和Web of Science等数据库获取了关于SLNB在子宫内膜癌、外阴癌、宫颈癌和卵巢癌中的研究。检索聚焦于以英文发表的同行评审文章、系统综述、荟萃分析、临床实践指南和专家共识声明。SLNBx是妇科恶性肿瘤分期中系统性淋巴结切除术的有效替代方案。其在外阴癌和子宫内膜癌分期中的地位已确立。对于宫颈癌，SENTICOL和SENTIX研究表明其具有高检出率，且生存结局与淋巴结切除术相当，同时并发症更少。在卵巢癌中，SLNBx的检出率参差不齐，需要进一步研究以确定SLNBx的作用。临床研究支持使用SLNBx对子宫内膜癌、外阴癌和宫颈癌进行分期。未来的研究和标准化方案对于确立SLNBx作为卵巢癌标准实践至关重要。
[英文摘要] Determination of lymph node metastasis is crucial for prognosis and treatment strategies for gynecologic cancers. Assessing metastases using a sentinel lymph node biopsy (SLNBx) approach decreases surgical morbidity and improves quality of life. This review evaluates the efficacy, safety, and clinical utility of SLNB in gynecologic cancers to inform clinical practice and highlight areas for future research. Endometrial, vulvar, cervical, and ovarian cancer studies on SLNB were obtained from databases including PubMed, Scopus, and Web of Science. The search focused on peer-reviewed articles, systematic reviews, meta-analyses, clinical practice guidelines, and expert consensus statements published in English. SLNBx is an effective alternative to systematic lymphadenectomy for staging gynecologic malignancies. It is established for vulvar and endometrial cancer staging. For cervical cancer, the SENTICOL and SENTIX studies demonstrate high detection rates and comparable survival outcomes to lymphadenectomy with fewer comorbidities. In ovarian cancer, SLNBx detection rates vary, and additional research is needed to determine the role of SLNBx. Clinical studies support the use of SLNBx for staging of endometrial, vulvar, and cervical cancers. Future research and standardized protocols are essential to establish SLNBx as a standard practice in ovarian cancer.
-
6. Amniotic Fluid Embolism: A Silent Threat to Maternal Life- An Up-to-Date Comprehensive Review of the Pathophysiology, Diagnosis, and Outcome.
PMID:日期:2026-06-01Amniotic fluid embolism is a serious complication of pregnancy where fetal cells, amniotic fluid, and debris enter the maternal circulation, leading to cardiovascular collapse, respiratory issues, and disseminated intravascular coagulation, which can cause acute hemorrhage. Although the exact cause of this embolization is unknown, it frequently occurs in healthy women during pregnancy, after obstetric procedures, or within 48 hours after delivery. Early symptoms of amniotic fluid embolism are often nonspecific, potentially leading to misdiagnosis and increased maternal mortality and morbidity. The goal of this review is to synthesize the current literature on early diagnosis methods, increase awareness and understanding of AFE, and ultimately improve outcomes for mothers and their babies. The importance of early recognition and intervention is also highlighted, as well as the potential for long-term complications such as cognitive disabilities in affected infants. We conducted a literature review and highlighted articles that pertained to the historical perspectives of the disease, its pathophysiology, diagnosis, and management. Sources, including PubMed, were used as search engines, and applicable articles were cited as references. AFE is one of the leading causes of maternal mortality and morbidity, as misdiagnosis is prevalent due to a lack of definitive diagnostic protocols for AFE. While new diagnostic methods are available, further study is needed to ensure that disease sensitivity is accurate. Further research is needed to understand the mechanism and presentation of AFE, as prompt intervention is associated with positive maternal and fetal outcomes.
-
7. A System Review of Pathophysiology, Diagnosis, and Clinical Management of Intrauterine Adhesions.
PMID:日期:2026-06-01Intrauterine adhesions are a major cause of menstrual abnormalities, infertility, and adverse obstetric outcomes, most commonly resulting from iatrogenic endometrial injury after uterine curettage. Despite advances in hysteroscopic treatment, prevention, recurrence, and endometrial regeneration remain unresolved clinical challenges. To elucidate the pathogenesis of intrauterine adhesions, particularly curettage-induced injury, and to summarize current diagnostic methods, classification systems, and evidence-based treatments, including emerging regenerative strategies to reduce adhesion formation and recurrence. PubMed, Web of Science, and Embase were searched for studies on IUA pathogenesis, diagnosis, and management, with emphasis on curettage methods, hysteroscopic treatment, adjuvant therapies, and emerging biological interventions. Evidence indicates that IUA develops through basal endometrial injury followed by dysregulated inflammation, impaired angiogenesis, and excessive fibrotic repair. Sharp curettage, particularly when repeated or unguided, confers a higher adhesion risk than vacuum aspiration. Hysteroscopy is the diagnostic gold standard and guides severity-based classification. Hysteroscopic adhesiolysis remains the primary treatment, with technique selection based on adhesion extent. Adjunctive therapies, including estrogen, antifibrotic agents, physical barriers, and emerging biologics, may enhance endometrial regeneration and reduce recurrence, though efficacy varies across disease severity. Clinicians should prioritize strategies that minimize endometrial trauma during uterine evacuation, including the preferential use of vacuum aspiration and image-guided techniques. Optimized hysteroscopic management combined with appropriate adjuvant therapies is essential to reduce recurrence and improve reproductive outcomes in women with IUAs.
-
8. Atrial Fibrillation and Atrial Flutter in Pregnancy: Epidemiology, Pathophysiology, and Management.
PMID:日期:2026-06-01The prevalence of atrial fibrillation (AF) and atrial flutter (AFL) among pregnant patients has increased over time, with AF now being the most common sustained cardiac arrhythmia in pregnancy. Management of AF/AFL in pregnancy presents unique clinical challenges, with careful consideration of both maternal and fetal well-being. To review the current evidence and expert guidance regarding the evaluation and management of AF and AFL in pregnancy, with emphasis on epidemiology, risk factors, pregnancy-specific considerations, and treatment strategies. Relevant literature on AF and AFL in pregnancy was reviewed, including epidemiologic data, pathophysiologic insights, pharmacologic and nonpharmacologic management approaches, and expert consensus guidelines. Key topics included maternal and fetal safety of commonly used medications, considerations for antepartum and intrapartum care, and strategies for addressing both stable and emergent arrhythmia presentations. AF and AFL in pregnancy are associated with increased maternal and fetal risks. Pregnancy-specific physiological changes increase susceptibility to arrhythmia and thromboembolic complications, highlighting the importance of timely recognition and multidisciplinary management. Antepartum and intrapartum care planning is essential, including strategies for rhythm and rate control, anticoagulation, and emergency interventions. As AF and AFL become more prevalent in pregnancy, clinicians must be equipped with knowledge of pregnancy-specific considerations and evidence-based management strategies to optimize maternal and fetal outcomes. Early recognition, individualized therapy, and multidisciplinary coordination are key to improving prognosis for both mother and child.
-
9. Heavy Menstrual Bleeding in the Gynecology Clinic: A Call for Awareness and Standardized Screening for Underlying Bleeding Disorders.
9. 妇科门诊中的月经过多：呼吁对潜在出血性疾病的认知和标准化筛查PMID:日期:2026-05-01[中文摘要] 重度月经出血（HMB）是全球近30%女性普遍存在的问题。在因HMB寻求妇科诊疗的女性中，相当一部分已被确定其HMB的病因为潜在的出血性疾病。然而在实际临床中，这些患者的出血性疾病存在严重的诊断不足，凸显出提高认识和检测水平的必要性。本文旨在对HMB与出血性疾病的相关文献进行综述，提高对二者相互关系的认识。此外，提出标准化的诊断流程，以帮助识别哪些HMB女性可能存在潜在出血性疾病并需要进一步的止血评估。通过PubMed进行文献检索，以识别关于HMB与出血性疾病的英文相关原始研究和综述文章。并以手工参考文献检索及英文和荷兰文相关指南的查阅作为补充。相当比例（10%至高达62%）的HMB女性存在潜在出血性疾病，但许多此类疾病未被识别。多种筛查工具，尤其是经过验证的PBAC、Philipp工具或自评出血评估工具（self-BAT），有助于区分伴或不伴疑似出血性疾病的HMB，并提示哪些患者需要额外的止血评估。潜在出血性疾病在HMB中的发生率远高于目前的认识。妇科医生应意识到这一点，并熟悉出血性疾病的筛查工具和诊断流程。妇科与血液科之间的多学科协作对于准确诊断和管理HMB女性潜在的出血性疾病至关重要。
[英文摘要] Heavy menstrual bleeding (HMB) is a common problem existing in nearly 30% of women worldwide. An underlying bleeding disorder has been identified as a cause of HMB in a significant proportion of women seeking gynecological care for HMB. In practice, however, there is a significant underdiagnosis of bleeding disorders in these patients, highlighting a need for improvement in awareness and detection. To present a comprehensive review of the literature on HMB and bleeding disorders and to increase awareness of their interrelation. In addition, to propose a standardized diagnostic approach to help identify which women with HMB may have an underlying bleeding disorder and require further hemostatic evaluation. A literature review was performed using PubMed to identify relevant primary research and review articles on the topic of HMB and bleeding disorders in English. This was supplemented by manual reference searches and review of relevant guidelines in English and Dutch. A significant proportion (10% to as much as 62%) of women with HMB have an underlying bleeding disorder, yet many such disorders go unrecognized. Various screening instruments, particularly the validated PBAC, Philipp tool or self-BAT, can help distinguish between HMB with or without a suspected bleeding disorder, and indicate who needs additional hemostatic evaluation. An underlying bleeding disorder is far more frequent in HMB than currently appreciated. Gynecologists should be aware of this and be familiar with screening instruments and a diagnostic workflow for bleeding disorders. Multidisciplinary collaboration between gynecology and hematology is crucial for accurately diagnosing and managing potential bleeding disorders in women with HMB.
-
10. Uterine Sarcomas: Clinical Management and a Review of Systemic Therapy.
PMID:日期:2026-05-01Uterine sarcomas are rare but aggressive tumors with high rates of recurrence and limited effective treatment options; a deeper understanding of their molecular and histologic diversity is critical to improving outcomes. To provide a comprehensive overview of clinical management and current systemic treatment strategies for uterine sarcomas. Specific histologic subtypes and molecular features are also reviewed. A thorough review of the literature was conducted using PubMed and clinical trial databases, with a focus on recent studies evaluating histology-specific management, molecular diagnostics, and novel systemic therapies across uterine sarcoma subtypes. Uterine sarcomas comprise 3% to 5% of uterine malignancies and include multiple distinct subtypes such as leiomyosarcoma, low and high-grade endometrial stromal sarcoma, undifferentiated uterine sarcoma, and adenosarcoma. Each displays unique clinical behavior and molecular alterations that guide treatment. While surgery remains the foundation of management for early-stage disease, the role of adjuvant therapy is unclear and best guided by individual risk. In advanced disease, combination regimens such as doxorubicin and trabectedin have shown improved outcomes in the treatment of leiomyosarcomas. Targeted therapies, hormonal agents, and immunotherapy have variable activity across subtypes. Molecular diagnostics, including next-generation sequencing, are increasingly essential in diagnosis, prognostication, and treatment planning. The landscape of uterine sarcoma treatment is rapidly evolving due to advances in molecular biology and emerging systemic therapies. Personalized management based on histology and molecular profiling, along with the development of subtype-specific clinical trials, will be essential in improving survival. Centralized, multidisciplinary care remains a cornerstone for patients with these rare tumors.